PRESS RELEASES
Visit of His Majesty the King of the Belgians Philippe and Her Majesty the Queen of the Belgians Mathilde to Afrigen Biologics
CAPE TOWN (SOUTH AFRICA) & BRUSSELS (BELGIUM), MARCH 25, 2023 – Belgian Royal delegation visits the Afrigen facilities where Univercells and Etherna will be supporting the development of the first African-owned mRNA COVID-19 vaccine.
Foundational RNA and cLNP expert Antonin (Tony) de Fougerolles joins Etherna as independent board member
Niel, Belgium, January 9, 2023 – Etherna (“the Company”), a leading mRNA technologies company, announced today that Antonin (Tony) de Fougerolles has joined its board of directors as an independent member. This follows the Company’s recent Series B2 financing round to expand investment in its integrated mRNA technology platform and further pursue its new partnership-driven business strategy.
mRNA specialist eTheRNA has been selected as a candidate for the M&A Award Life Sciences 2022
Niel, Belgium, November 10, 2022 – eTheRNA, a leading mRNA technology company, announces its nomination for the Belgian M&A Awards 2022 in the “Best Venture Capital Deal – Life Sciences 2022” category. The nomination of eTheRNA is based on its successful Series B financing in August 2022, in which eTheRNA raised €39 million of fresh capital from reputable investors.
mRNA leading expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers investing in EUR 39M Series B2 financing of mRNA technology platform company eTheRNA
- Financing round led by Novalis LifeSciences LLC
- Both investors Dr. Marijn Dekkers and Moderna’s co-founder Dr. Kenneth Chien to join the board of directors
- Strategic focus includes customized lipid nanoparticles (cLNPs)
- Current COO Bernard Sagaert appointed interim-CEO
Niel, Belgium, August 23, 2022 – eTheRNA (“the Company”), a leading mRNA technologies company, announced today that it has raised €39M in a Series B2 financing to expand investment in its integrated mRNA technology platform and further pursue its new initiatives for a partnership-driven business strategy. The round was led by Novalis LifeSciences with participation from Professor Kenneth Chien, a world-renowned expert in mRNA technology and its therapeutic applications. Existing investors, including LSP (now EQT Life Sciences), PMV, Grand Pharma, Fund+, Omega Fund, and others, also participated in the financing.
Galileilaan 19, 2845 Niel, Belgium
Our Address
info@etherna.be
Our Mailbox
+32 3 369 17 40
Our Phone
© 2023 eTheRNA | Studio Hanswijk